Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
AstraZeneca (AZN) Share Price & Analysis
312 Followers
AZN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range9,314.90p - 12,488.00p
Previous Close12,096p
Volume258.09K
Average Volume (3M)2.79M
Market Cap
£187.52B
Enterprise Value205.46B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)37.3
Beta0.91
Next Earnings
Jul 25, 2024EPS Estimate
£1.58Last Dividend Ex-Date
Feb 22, 2024Dividend Yield1.88%
Share Statistics
EPS (TTM)3.25
Shares Outstanding1,550,189,338
10 Day Avg. Volume2,944,327
30 Day Avg. Volume2,790,955
Standard Deviation0.06
R-Squared0.09
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-12.49
Price to Sales (P/S)486.49
Price to Cash Flow (P/CF)21.60
P/FCF Ratio29.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.63
Enterprise Value/Gross Profit5.47
Enterprise Value/Ebitda22.62
Forecast
1Y Price Target
12,355.40pPrice Target Upside-0.35% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
AstraZeneca News
PremiumCompany Announcements
AstraZeneca Targets $80 Billion Revenue by 2030
PremiumCompany Announcements
AstraZeneca’s $1.5B ADC Facility in Singapore
PremiumGlobal Markets
AstraZeneca Sharpens Focus on Innovation
PremiumCompany Announcements
AstraZeneca’s Breakthrough in COVID-19 Protection for High-Risk Patients
PremiumCompany Announcements
AstraZeneca CEO Granted Performance-Based SharesBulls Say, Bears Say
Bulls Say
Drug DevelopmentEnhertu is viewed optimistically for both neoadjuvant and post-neoadjuvant settings, potentially expanding its use in breast cancer therapy.
Financial PerformanceA 2030 revenue target is likely to be set above current consensus figures, which suggests strong growth prospects.
Pipeline PotentialAZN has 5 game-changing Phase III reads for key assets with a total circa $20bn sales potential, demonstrating a robust pipeline.
Bears Say
Drug Development DelaysEplontersen Phase III read shift to FY26, indicating a longer timeline for potential revenue from this asset.
Financial GuidanceThe only disappointment is the lack of the guidance upgrade given current implied guidance is below consensus.
Stock PerformanceShares have been underperforming due to factors such as near-term EPS momentum and misinterpreted margin comments.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.18% Insiders
14.32% Mutual Funds
8.17% Other Institutional Investors
77.33% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9314.90p and its highest was 12488.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Jul 25, 2024 which is in 65 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Apr 25, 2024. The company reported 1.621p earnings per share for the quarter, beating the consensus estimate of 1.504p by 0.117p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Overvalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 156p which represents an annual dividend yield of 1.88%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is £1.58.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,235,000 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.621p in its last earnings report, beating expectations of 1.504p. Following the earnings report the stock price went up 5.937%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
12,355.40p (-0.35% Downside)
12,355.40p (-0.35% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.95%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
3.55%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
12,355.40p
▼(-0.35% Downside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
29/34 ratings generated profit
1 Year Average Return
+14.32%
reiterated a buy rating 26 days ago
Copying Emily Field's trades and holding each position for 1 Year would result in 85.29% of your transactions generating a profit, with an average return of +14.32% per trade.
---